Orthofix gained FDA premarket approval and approval under the CE Mark in the EU for next-gen PhysioStim™ bone growth stimulators, used as a nonsurgical treatment for nonunion fracture in the extremities.
The Class III device emits a pulsed electromagnetic field signal at the fracture site to stimulate bone healing, and is complemented by the STIM onTrack™ mobile app for patient compliance and education.
Orthofix is conducting IDE clinical trials of Physio-Stim in the treatment of knee OA, the RCStim™ system as an adjunct to surgery in the repair of full-thickness rotator cuff tears and Cervical-Stim to treat odontoid fractures.
Orthofix gained FDA premarket approval and approval under the CE Mark in the EU for next-gen PhysioStim™ bone growth stimulators, used as a nonsurgical treatment for nonunion fracture in the extremities.
The Class III device emits a pulsed electromagnetic field signal at the fracture site to stimulate bone healing, and is complemented by...
Orthofix gained FDA premarket approval and approval under the CE Mark in the EU for next-gen PhysioStim™ bone growth stimulators, used as a nonsurgical treatment for nonunion fracture in the extremities.
The Class III device emits a pulsed electromagnetic field signal at the fracture site to stimulate bone healing, and is complemented by the STIM onTrack™ mobile app for patient compliance and education.
Orthofix is conducting IDE clinical trials of Physio-Stim in the treatment of knee OA, the RCStim™ system as an adjunct to surgery in the repair of full-thickness rotator cuff tears and Cervical-Stim to treat odontoid fractures.
Copy to clipboard 
